Abstract: An intravascular stent has a coating comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coating comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: A pharmaceutical composition for embolization of blood vessels, especially for benign tumours, comprises a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic agent. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer Is a crosslinked polyvinyl alcohol polymer formed by the copolymerization of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of tumours such as uterine fibrioids, leading to size regression as well as pain relief.

Abstract: A method of producing an intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2?-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: An intravascular stent has a coat comprising a crosslinked amphiphilic polymer and a sparingly water soluble matrix metalloproteinase inhibitor (MMPI). Preferably the polymer is formed from 2-methacryloyloxy-2′-ethyltrimethylammonium phosphate inner salt, C4-18 alkyl methacrylate and reactive and/or crosslinking monomer and the MMPI is a hydroxamic acid, more preferably batimastat. Preclinical and clinical results are reported, showing good luminal areas and reduced intimal thickening.

Abstract: A non-crosslinked biocompatible polymer is formed from a radical polymerisable ethylenically unsaturated zwitterionic monomer containing a sulpho-betaine zwitterionic group and a radical polymerisable ethylenically unsaturated comonomer containing a hydrophobic group selected from C6-24-alkyl, C1-24-fluoroalkyl and siloxane groups. Suitable copolymers are of N,N-dimethyl ammonium-N-propylsulphonate-N-ethyl methacrylate and dodecylmethacrylate. The polymer may be used to coat substrates to render them biocompatible, especially hemocompatible. The hydrophobic groups render the polymer particularly suitable for coating hydrophobic substrates.

Abstract: Polymers of one or more radical polymerisable monomers which polymer has pendant groups bearing a centre of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

Abstract: Polymers of one or more radical polymerisable monomers which polymer has pendant groups bearing a centre of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

Abstract: Polymers of one or more radical polymerisable monomers which polymer has pendant groups bearing a center of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

Abstract: Polymers of one or more radical polymerisable monomers which polymer has pendant groups bearing a center of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

Abstract: Polymers of one or more radical polymerizable monomers which polymer has pendant groups bearing a center of permanent positive charge and other pendant groups capable of stably binding the polymer to a surface are useful in the treatment of surfaces to render them biocompatible. The polymers may contain pendant groups which bind the polymer to a surface by physisorption, covalent bonding or ionic interactions. Additionally reactive groups in the polymer may serve as points for attachment of ligands to the polymer when coated on a surface.

Abstract: A process for the preparation of compounds of formula (I) in which Z is hydrogen or --NHZ is an activated amine group capable of reacting with a surface, the groups R are the same or different and each is a straight or branched C.sub.1 -C.sub.4 alkyl group, preferably methyl, n is from 2 to 6, and X is a straight or branched C.sub.1-20 alkylene group, or X is a group of formula --(CH.sub.2 CH.sub.2 O).sub.b --, or --(CH.sub.2).sub.c --Ar--(CH.sub.2).sub.d -- where b is from 1 to 20, c and d are the same or different and each is from 0 to 5, and Ar is a para- or meta- disubstituted phenyl group (preferably a para-disubstituted phenyl group) which is optionally further substituted by one or more C.sub.1 -C.sub.4 alkyl groups, or an acid addition salt thereof or a hydrate thereof, new compounds of formula (I) and salts and hydrates thereof and the use of compounds of formula (I) and salts and hydrates thereof in treating surfaces to render them more biocompatible.